KPV
Also known as: Lys-Pro-Val, Alpha-MSH fragment
Buy in shop
KPV
5 verified vendors, side by side on real prices.
Key Facts: KPV
- Category
- Immune
- FDA Status
- Not FDA Approved
- Clinical Status
- Preclinical - FDA removed KPV from Category 2 effective April 22, 2026. PCAC voted to recommend KPV for the 503A authorized compounding bulks list on July 23, 2026. Non-binding advisory recommendation; formal FDA rulemaking required before any legal compounding change. No FDA approval for any indication. Effective October 30, 2026, HHS published Federal Register Document 2026-22192, an interim enforcement discretion policy that conditionally permits 503A compounding pharmacies to compound KPV while formal rulemaking proceeds. Conditions include pharmaceutical-grade API sourcing, certificates of analysis, patient-specific prescriptions only, and single-API formulations only. This does not add KPV to the FDA 503A Bulks Drug Substances List and is not a final rule. Rulemaking is pending with no timeline stated.
- Banned in Sport (WADA)
- Not named on the WADA list, but WADA's S0 catch-all bans any substance without human therapeutic approval, which covers it. Prohibited at all times.
- Administration
- Subcutaneous injection or oral (capsules)
- Typical Dose
- 200-500 mcg daily
- Frequency
- 1-2x daily
- Duration
- 4-8 weeks typical
How does KPV work?
What makes KPV interesting is how it gets into cells. Research suggests it hitches a ride on a nutrient transporter called PepT1, which is normally found in the small intestine but gets switched on in the colon during inflammation. Once inside the cell, KPV appears to interfere with NF-kB, a master switch that turns on inflammatory genes, which in lab studies reduces output of pro-inflammatory signals like TNF-alpha, IL-1beta, and IL-6. Unlike its parent hormone alpha-MSH, KPV does not seem to activate the classic melanocortin receptors, so its proposed action is described as largely receptor-independent. These mechanisms are supported by laboratory work but should be treated as a working model, not settled fact.
What does the research show?
The honest picture: KPV's reputation rests on animal and in vitro research, not human trials. A frequently cited study in Gastroenterology (Dalmasso and colleagues, 2008) showed PepT1-mediated uptake of KPV reduced intestinal inflammation, and oral KPV lessened chemically induced colitis (DSS and TNBS models) in mice while lowering pro-inflammatory cytokines. A later 2016 study in PMC reported KPV also reduced tumor number in a mouse model of colitis-associated cancer in a PepT1-dependent way. These are genuinely interesting, reproducible animal findings. But there are no published randomized controlled trials in humans for inflammatory bowel disease, eczema, or any of the conditions it is marketed for. Claims that it treats Crohn's, leaky gut, or mast cell activation in people are extrapolations from rodent data, not proven outcomes.
What doses have been studied?
Note: Animal study doses may not translate directly to humans.
Typical Dosingⓘ
Community experience
200-500 mcg daily
100-1000 mcg daily
1-2x daily
An anti-inflammatory tripeptide studied in gut inflammation and dermatological conditions. Reported use covers both systemic and localized administration.
Research Dosingⓘ
Scientific studies
Doses from research protocols
Doses from Studies
200-500 mcg daily
Oral or subcutaneous
Duration
4-8 weeks typical
Administration
Subcutaneous injection or oral (capsules)
When and how is KPV taken?
Best Time to Take
Morning or as directed
Once daily
Food Recommendation
With or without food
Why This Timing?
KPV is an anti-inflammatory peptide. Morning use for daytime inflammation management.
What are the side effects of KPV?
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Generally very well-tolerated
- ●Injection site reactions
- ●Mild flu-like symptoms (transient)
- ●Mild GI effects
- ●May trigger histamine release - use caution with MCAS or histamine sensitivity
- ●Does NOT cause immunosuppression
- ●Contraindicated with cancer history
References
- https://pmc.ncbi.nlm.nih.gov/articles/PMC4957955/
- https://www.gastrojournal.org/article/S0016-5085(07)01852-5/fulltext
- https://pubmed.ncbi.nlm.nih.gov/27458604/
- https://www.federalregister.gov/documents/2026/10/30/2026-22192/compounding-enforcement-discretion-503a
Research This Peptide Further
Buy in shop
KPV
5 verified vendors, side by side on real prices.
Frequently Asked Questions
What does KPV do?
KPV is a tiny tripeptide, just three amino acids (lysine, proline, valine), that forms the tail end of the natural hormone alpha-MSH. It is studied almost entirely as an anti-inflammatory agent, particularly for gut and skin inflammation. There are no registered human clinical trials proving its benefits in people; the evidence base is cell-culture and animal studies, so anything you read about it treating disease is preliminary.
How does KPV work?
What makes KPV interesting is how it gets into cells. Research suggests it hitches a ride on a nutrient transporter called PepT1, which is normally found in the small intestine but gets switched on in the colon during inflammation. Once inside the cell, KPV appears to interfere with NF-kB, a master switch that turns on inflammatory genes, which in lab studies reduces output of pro-inflammatory signals like TNF-alpha, IL-1beta, and IL-6. Unlike its parent hormone alpha-MSH, KPV does not seem to activate the classic melanocortin receptors, so its proposed action is described as largely receptor-independent. These mechanisms are supported by laboratory work but should be treated as a working model, not settled fact.
Is KPV FDA approved?
No, KPV is not currently FDA approved. Current status: Preclinical - FDA removed KPV from Category 2 effective April 22, 2026. PCAC voted to recommend KPV for the 503A authorized compounding bulks list on July 23, 2026. Non-binding advisory recommendation; formal FDA rulemaking required before any legal compounding change. No FDA approval for any indication. Effective October 30, 2026, HHS published Federal Register Document 2026-22192, an interim enforcement discretion policy that conditionally permits 503A compounding pharmacies to compound KPV while formal rulemaking proceeds. Conditions include pharmaceutical-grade API sourcing, certificates of analysis, patient-specific prescriptions only, and single-API formulations only. This does not add KPV to the FDA 503A Bulks Drug Substances List and is not a final rule. Rulemaking is pending with no timeline stated.
Is KPV banned in sport?
Not named on the WADA list, but WADA's S0 catch-all bans any substance without human therapeutic approval, which covers it. Prohibited at all times.
What are the side effects of KPV?
Reported side effects include: Generally very well-tolerated, Injection site reactions, Mild flu-like symptoms (transient), Mild GI effects, May trigger histamine release - use caution with MCAS or histamine sensitivity. Individual responses vary based on dosage, duration, and personal health factors.
What is the typical dose of KPV?
Community-reported common dose: 200-500 mcg daily (1-2x daily). Range: 100-1000 mcg daily. Administration: Subcutaneous injection or oral (capsules). Community-reported doses. Not medical advice. Consult healthcare provider.
Related Peptides
Peptides commonly compared with KPV or used in similar applications.
LL-37
Clinical TrialsLL-37 is the only cathelicidin antimicrobial peptide humans make, a 37-amino-acid, positively charged, helical fragment cut from a precursor protein called hCAP-18. It is a frontline player in the innate immune system, part of the body's chemical defense against bacteria, viruses, and fungi. This is mainstream, heavily studied human biology, not a fringe research peptide, though LL-37 itself is not an approved drug.
ImmuneThymosin Alpha-1
Clinical TrialsThymosin alpha-1 (sold as Zadaxin, generic name thymalfasin) is a 28-amino-acid peptide originally isolated from the thymus gland, the organ that trains your immune system. Unlike most peptides in this space, it is a real, approved drug in a number of countries, including China and Italy, mainly for chronic hepatitis B and as an immune booster, though it has never been approved by the FDA in the United States. It has one of the larger human evidence bases of any peptide here, with more than 30 trials and over 11,000 subjects.
ImmuneVIP
Clinical TrialsVIP (vasoactive intestinal peptide) is a 28-amino-acid signaling peptide your own gut, nerves, and immune cells make, first isolated in 1970 by Said and Mutt. It is a natural anti-inflammatory and a potent vasodilator, and a synthetic version called aviptadil was tested in humans for COVID-19 respiratory failure, where the largest trial was negative. No VIP product is FDA-approved, including for the wellness, anti-aging, or mold-illness uses it gets marketed for.
ImmuneThymogen
Clinical TrialsThymogen is the brand name for L-Glu-L-Trp (glutamyl-tryptophan, the dipeptide EW), an immune-modulating peptide isolated from the calf thymus extract Thymalin. It is the smallest active piece of that thymic complex and is studied for boosting T-cell activity and immune function. It has been used clinically in Russia since 1990 but has never been evaluated or approved by any Western regulator, and rigorous independent trials are lacking.
ImmuneLarazotide acetate
Clinical TrialsLarazotide is an 8-amino-acid oral peptide (GGVLVQPG) designed to tighten the junctions between gut lining cells, aimed at celiac disease. For years it was the furthest-along celiac drug in development and it gets talked about online as a 'leaky gut' or zonulin blocker. The honest story is short: one phase 2b trial found a modest symptom benefit at the lowest dose only, the phase 3 trial was stopped in 2022 when it could not show a clear effect, and the sponsor 9 Meters Biopharma filed for Chapter 7 liquidation in July 2023. It is not approved anywhere.
ImmuneThymulin
PreclinicalThymulin is a tiny nine-amino-acid hormone made by the epithelial cells of the thymus, first described in the 1970s as facteur thymique serique (FTS). It only works when bound to one zinc atom, which makes it an oddly neat marker of zinc status. It plays a part in training T cells, and animal work suggests anti-inflammatory and pain-reducing effects. It is sold online for immune support and hair loss, but there are no modern human trials of giving it, and the hair claims rest on lab dishes and a sponsor-linked cosmetic study.
ImmuneWant updates on KPV research?
Get an email when we add new research here, when it is back in stock, or when the price drops.